RecruitingPhase 4ACTRN12608000537358
Metabolic effects of oestrogen compounds in men with low testosterone
Metabolic effects of SERMs (Selective Oestrogen Receptor Modulators) in hypogonadal men
Sponsor
Department of Endocrinology, St Vincent's Hospital
Enrollment
24 participants
Start Date
Feb 6, 2008
Study Type
Interventional
Conditions
Summary
We aim to investigate the effects of raloxifene (SERM) in hypogonadal men on the growth hormone system and metabolism.
Eligibility
Sex: MalesMin Age: 40 YearssMax Age: 80 Yearss
Inclusion Criteria1
- Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)
Exclusion Criteria1
- Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Raloxifene (120 mg) as 2 oral tablets a day for 6 months
Raloxifene (120 mg) as 2 oral tablets a day for 6 months
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000537358